Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

azacytidine bcl-2 blastic bpdcn cd123 dendritic neoplasm plasmacytoid rare venetoclax

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Apr 2023
Historique:
accepted: 01 04 2023
medline: 8 4 2023
entrez: 7 4 2023
pubmed: 8 4 2023
Statut: epublish

Résumé

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematological tumor originating from the precursor of plasmacytoid dendritic cells (pDCs) with a persistent and progressive course of illness. Despite being an aggressive disease BPDCN has an initial indolent course manifested as skin lesions. Alongside or following the skin lesion, the extra-cutaneous manifestation develops and includes lymphadenopathy, splenomegaly, and hepatomegaly. The BPDCN diagnosis is mainly based on the immunophenotype.  Herein, we report the case of a 72-year-old male patient who presented with a history of left anterior chest wall painless skin lesions. Histology of skin biopsy of the left chest skin lesion showed diffuse dermal infiltration by monomorphic medium-sized blastic cells positive for cluster of differentiation (CD)4, CD45, CD7, CD56, CD43, CD123, T-cell leukemia-1 (TCL1), and B-cell leukemia/lymphoma 2 protein (BCL2). Given the rarity of the disease, standard chemotherapy regimens used in treating different leukemias and lymphomas have been adapted to treat BPDCN.

Identifiants

pubmed: 37026111
doi: 10.7759/cureus.37016
pmc: PMC10072177
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e37016

Informations de copyright

Copyright © 2023, Nasiri et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Clin Pathol. 2005 May;123(5):662-75
pubmed: 15981806
Br J Dermatol. 2003 Oct;149(4):869-76
pubmed: 14616384
Expert Opin Investig Drugs. 2018 Sep;27(9):733-739
pubmed: 30118336
Am J Surg Pathol. 2014 May;38(5):673-80
pubmed: 24441662
Hematol Oncol Clin North Am. 2020 Jun;34(3):575-587
pubmed: 32336421
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):734-740
pubmed: 34226167
Eur J Haematol. 2014 Jul;93(1):81-5
pubmed: 24571716
J Am Acad Dermatol. 2008 Mar;58(3):480-4
pubmed: 18280345
Leuk Res. 2010 Apr;34(4):438-46
pubmed: 19793612
Cancer. 2002 May 1;94(9):2401-8
pubmed: 12015765
Am J Clin Pathol. 2007 Sep;128(3):445-53
pubmed: 17709319
Leuk Res. 2012 Jan;36(1):81-6
pubmed: 21890199
Br J Haematol. 2016 Jul;174(2):188-202
pubmed: 27264021
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):545-554
pubmed: 31281107
Blood. 2002 Mar 1;99(5):1556-63
pubmed: 11861268
Biol Blood Marrow Transplant. 2013 Jul;19(7):1006-12
pubmed: 23396213
Cancers (Basel). 2019 Apr 28;11(5):
pubmed: 31035408
Haematologica. 2013 Feb;98(2):239-46
pubmed: 23065521
Am J Hematol. 1994 Dec;47(4):278-82
pubmed: 7526680
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood Adv. 2019 Dec 23;3(24):4238-4251
pubmed: 31869411
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):16-23
pubmed: 27913457
Blood. 2002 Jun 1;99(11):4154-9
pubmed: 12010820

Auteurs

Abdulrahman Nasiri (A)

Hematology, King Faisal Specialist Hospital & Research Centre, Riyadh, SAU.

Arwa Lami (A)

Internal Medicine, Security Forces Hospital, Riydah, SAU.

Alanoud Alhumaidi (A)

Internal Medicine, Security Forces Hospital, Riyadh, SAU.

Afnan Madkhali (A)

Internal Medicine, Security Forces Hospital, Riyadh, SAU.

Amnah Althaqib (A)

Internal Medicine, Security Forces Hospital, Riyadh, SAU.

Norah Aljarwan (N)

Internal Medicine, Security Forces Hospital, Riyadh, SAU.

Reem Alkharras (R)

Internal Medicine, Security Forces Hospital, Riyadh, SAU.

Classifications MeSH